Immunocore (NASDAQ:IMCR) Reaches New 12-Month Low at $32.07

Immunocore Holdings plc (NASDAQ:IMCR)’s stock price reached a new 52-week low during trading on Monday . The company traded as low as $32.07 and last traded at $32.07, with a volume of 6743 shares trading hands. The stock had previously closed at $33.18.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IMCR. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Tuesday, September 17th. Oppenheimer reissued an “outperform” rating and issued a $89.00 price objective (up from $87.00) on shares of Immunocore in a research report on Friday, August 9th. JPMorgan Chase & Co. cut their target price on Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 10th. Needham & Company LLC lowered their target price on Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Immunocore has an average rating of “Moderate Buy” and a consensus target price of $80.40.

Immunocore Stock Performance

The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -27.20 and a beta of 0.73. The company’s fifty day simple moving average is $36.84 and its two-hundred day simple moving average is $46.38. The company has a debt-to-equity ratio of 1.31, a current ratio of 5.17 and a quick ratio of 5.15.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.25. The company had revenue of $75.40 million for the quarter, compared to analyst estimates of $74.58 million. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The firm’s revenue was up 26.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.37) EPS. On average, analysts forecast that Immunocore Holdings plc will post -1.79 earnings per share for the current year.

Institutional Investors Weigh In On Immunocore

Several institutional investors have recently bought and sold shares of the stock. DNB Asset Management AS boosted its holdings in Immunocore by 35.0% during the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after acquiring an additional 1,868 shares during the last quarter. NEOS Investment Management LLC bought a new stake in Immunocore in the 4th quarter worth about $262,000. XTX Topco Ltd purchased a new stake in Immunocore in the 2nd quarter valued at about $303,000. Tidal Investments LLC bought a new position in shares of Immunocore during the 1st quarter worth approximately $423,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Immunocore by 69.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock worth $430,000 after buying an additional 2,721 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.